Skip to main content

Table 1 Mean percent change from baseline in LDL-C levels in pivotal and extension studies

From: Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

Time point

n

Observed value, mg/dL (SD)

Observed change, mg/dL (SD)

Percent change, % (SD)

Baseline

19

342.8 (125.87)

NA

NA

Week 26

19

158.4 (89.65)

− 184.4 (119.15)

−50.7 (26.77)

Week 78

19

161.2 (59.55)

− 181.7 (110.76)

− 49.0 (19.46)

Week 126

17

188.8 (120.30)

−166.8 (100.28)

−45.5 (31.35)

Week 256

14

143.4 (83.18)

− 224.9 (108.97)

−60.1 (18.51)

  1. LDL-C Low-density lipoprotein cholesterol. Values represent percent change in LDL-C levels ± SD from baseline for patients entering the long-term extension study [6]. Background lipid-lowering therapies were fixed until Week 26. Week 78 marks the beginning of the extension phase